Cargando…

IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome

Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype awai...

Descripción completa

Detalles Bibliográficos
Autores principales: Araya, Paula, Kinning, Kohl T., Coughlan, Christina, Smith, Keith P., Granrath, Ross E., Enriquez-Estrada, Belinda A., Worek, Kayleigh, Sullivan, Kelly D., Rachubinski, Angela L., Wolter-Warmerdam, Kristine, Hickey, Francis, Galbraith, Matthew D., Potter, Huntington, Espinosa, Joaquin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876612/
https://www.ncbi.nlm.nih.gov/pubmed/36577365
http://dx.doi.org/10.1016/j.celrep.2022.111883
_version_ 1784878200945377280
author Araya, Paula
Kinning, Kohl T.
Coughlan, Christina
Smith, Keith P.
Granrath, Ross E.
Enriquez-Estrada, Belinda A.
Worek, Kayleigh
Sullivan, Kelly D.
Rachubinski, Angela L.
Wolter-Warmerdam, Kristine
Hickey, Francis
Galbraith, Matthew D.
Potter, Huntington
Espinosa, Joaquin M.
author_facet Araya, Paula
Kinning, Kohl T.
Coughlan, Christina
Smith, Keith P.
Granrath, Ross E.
Enriquez-Estrada, Belinda A.
Worek, Kayleigh
Sullivan, Kelly D.
Rachubinski, Angela L.
Wolter-Warmerdam, Kristine
Hickey, Francis
Galbraith, Matthew D.
Potter, Huntington
Espinosa, Joaquin M.
author_sort Araya, Paula
collection PubMed
description Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS.
format Online
Article
Text
id pubmed-9876612
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-98766122023-01-25 IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome Araya, Paula Kinning, Kohl T. Coughlan, Christina Smith, Keith P. Granrath, Ross E. Enriquez-Estrada, Belinda A. Worek, Kayleigh Sullivan, Kelly D. Rachubinski, Angela L. Wolter-Warmerdam, Kristine Hickey, Francis Galbraith, Matthew D. Potter, Huntington Espinosa, Joaquin M. Cell Rep Article Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS. 2022-12-27 /pmc/articles/PMC9876612/ /pubmed/36577365 http://dx.doi.org/10.1016/j.celrep.2022.111883 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Araya, Paula
Kinning, Kohl T.
Coughlan, Christina
Smith, Keith P.
Granrath, Ross E.
Enriquez-Estrada, Belinda A.
Worek, Kayleigh
Sullivan, Kelly D.
Rachubinski, Angela L.
Wolter-Warmerdam, Kristine
Hickey, Francis
Galbraith, Matthew D.
Potter, Huntington
Espinosa, Joaquin M.
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title_full IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title_fullStr IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title_full_unstemmed IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title_short IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
title_sort igf1 deficiency integrates stunted growth and neurodegeneration in down syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876612/
https://www.ncbi.nlm.nih.gov/pubmed/36577365
http://dx.doi.org/10.1016/j.celrep.2022.111883
work_keys_str_mv AT arayapaula igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT kinningkohlt igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT coughlanchristina igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT smithkeithp igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT granrathrosse igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT enriquezestradabelindaa igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT worekkayleigh igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT sullivankellyd igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT rachubinskiangelal igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT wolterwarmerdamkristine igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT hickeyfrancis igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT galbraithmatthewd igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT potterhuntington igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome
AT espinosajoaquinm igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome